These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11896482)

  • 1. Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction.
    Heaton JP; Dean J; Sleep DJ
    Int J Impot Res; 2002 Feb; 14(1):61-4. PubMed ID: 11896482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterising the benefit of apomorphine SL (Uprima) as an optimised treatment for representative populations with erectile dysfunction.
    Heaton JP
    Int J Impot Res; 2001 Aug; 13 Suppl 3():S35-9. PubMed ID: 11477490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of apomorphine SL (Uprima).
    Bukofzer S; Livesey N
    Int J Impot Res; 2001 Aug; 13 Suppl 3():S40-4. PubMed ID: 11477491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine SL (Uprima): a new treatment for the management of erectile dysfunction.
    Wagner G
    Int J Impot Res; 2001 Aug; 13 Suppl 3():S1-2. PubMed ID: 11477485
    [No Abstract]   [Full Text] [Related]  

  • 5. Sublingual apomorphine: new preparation. In erectile disorders: a narrow therapeutic margin.
    Prescrire Int; 2002 Jun; 11(59):76-9. PubMed ID: 12068841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men.
    Gontero P; D'Antonio R; Pretti G; Fontana F; Panella M; Kocjancic E; Allochis G; Frea B
    Int J Impot Res; 2005; 17(1):80-5. PubMed ID: 15510184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction.
    Von Keitz AT; Ströberg P; Bukofzer S; Mallard N; Hibberd M
    BJU Int; 2002 Mar; 89(4):409-15. PubMed ID: 11872034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and safety of apomorphine SL (Ixense (TM) ).
    Montorsi F
    Int J Impot Res; 2003 Apr; 15 Suppl 2():S7-9. PubMed ID: 12825097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction.
    Mulhall JP; Bukofzer S; Edmonds AL; George M;
    Clin Ther; 2001 Aug; 23(8):1260-71. PubMed ID: 11558862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating dose regimens of apomorphine, an open-label study.
    Kongkanand A; Opanuraks J; Tantiwongse K; Choeypunt N; Tantiwong A; Amornvejsukit T
    Int J Impot Res; 2003 Apr; 15 Suppl 2():S10-2. PubMed ID: 12825098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine to Uprima: the development of a practical erectogenic drug: a personal perspective.
    Morales A
    Int J Impot Res; 2001 Aug; 13 Suppl 3():S29-34. PubMed ID: 11477489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral treatment of erectile dysfunction with apomorphine SL.
    Altwein JE; Keuler FU
    Urol Int; 2001; 67(4):257-63. PubMed ID: 11741126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption of apomorphine by various routes in parkinsonism.
    Gancher ST; Nutt JG; Woodward WR
    Mov Disord; 1991; 6(3):212-6. PubMed ID: 1922125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experiences with apomorphine SL in studies: tolerated therapy--even in problem patients].
    MMW Fortschr Med; 2002 May; Suppl 2():83. PubMed ID: 12070860
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group.
    Dula E; Keating W; Siami PF; Edmonds A; O'neil J; Buttler S
    Urology; 2000 Jul; 56(1):130-5. PubMed ID: 10869641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging oral drugs for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
    Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction.
    Maclennan KM; Boshier A; Wilton LV; Shakir SA
    BJU Int; 2006 Jul; 98(1):125-31. PubMed ID: 16831156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous system-acting ED drug.
    Giuliano F; Allard J
    Int J Impot Res; 2002 Feb; 14 Suppl 1():S53-6. PubMed ID: 11850736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evaluation of apomorphine for the treatment of erectile dysfunction.
    Mohee A; Bretsztajn L; Eardley I
    Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1447-53. PubMed ID: 22998347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.
    Dula E; Bukofzer S; Perdok R; George M;
    Eur Urol; 2001 May; 39(5):558-3; discussion 564. PubMed ID: 11464037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.